



Psychiatric Medication and Well-Being in Persons with IDD

When is it reasonable, when not?


Good Clinical Practice

EAMHID-Masterclass, Bucharest, 23.11.2019

Dr. Brian Fergus Barrett Head of Adult Psychiatry and Psychotherapy in IDD Liebenau Clinics, Germany DGPPN – DGSGB – EAMHID











Somatic Disorders

Genetic Syndromes

Autism

Psychiatric Disorders

Behavior Impairment

Dietetic Therapy Analgesia Palliative Therapy		Pharmacotherapy Substitution-Therapy (e. g. Hormones)	
	Multimodal Therapy		
Physiotherapy Physical Therapy Assisitive Devices		Operative Therapie Interventional Therapy (z. B. ERCP)	






Somatic Disorders

Genetic Syndromes

Autism

Psychiatric Disorders

Behavior Impairment










Genetic Syndromes

Autism

Psychiatric Disorders

Behavior Impairment








Somatic Disorders

Genetic Syndromes

Autism

Psychiatric Disorders

Behavior Impairment








Somatic Disorders

Genetic **Syndromes**

Autism

Psychiatric Disorders

Behavior Impairmant







Pharmacotherapy

Milieutherapy

Psycho-

education

"In the years to come, the retarded may claim an all-time record of having the greatest variety and largest tonnage of chemical agents shoveled into them"

In 1958, just a few years after the introduction of the first neuroleptic drug Chlorpromazin, the American

Psychiatrist Dr. Theodore Greiner predicted:





Milieutherapy

Less is more!

Psychoeducation

Psychotherapy





Pharmacotherapy Less High-Dose-Neurolepicts

Milieutherapy

Less High-Potency-Neuroleptics

Psychoeducation "Start low, go slow"

Less Polypharmacy

Psychotherapy Reduced maximum dose

Intensive monitoring for ADR

Use of interaction-databases (e. g. drugs.com)





Milieutherapy

Impulsivity und Impaired Behavior

- Risperidone up to 1,5mg (licensed for CAP)
- Adults: Risperidone up to 2mg, max. 3mg (Off-Label)
- Quetiapine up to 300mg, max. 400mg (Off-Label)
 - Combination of immidiate and time released
- Zuclopenthixole up to 50mg (licensed for adults)
 - Frequent ADR
- Alternatives to Neuroleptics
 - Emotion- und Impulseregulation: VPA, Lithium
 - Frontal-Lobe-Syndrome: SSRI
 - Gabaergic: Pregabaline



Psychotherapy





Pharmacotherapy

Psychotic Disorders, Schizophrenia

- High-potency-neuroleptics
 - Risperidone up to 3mg, max. 4mg
 - Quetiapine up to 400mg, max. 600mg
 - Clozapine problematic
 - Anticholinergic ADR (Delirium among others)
 - Deterioration of cognition
 - Aripiprazol
 - May improve negative symptoms
 - Asenapin
 - Administration can be difficult

Milieutherapy

Psychoeducation





Epilepsy

- Levetiracetam
 - Dose >1500mg/d may contribute to aggression
 - Alternative: Brivaracetam

Milieutherapy

- Barbiturates
 - Deterioration of cognition
- Psychoeducation
- Forced normalization
 - May increase psychotic symptoms/behavior problems
- Psychotherapy
- Neuroleptics
 - Possible provocation of seizures (esp. Clozapine)
 - Exception: Melperone (low-potency)





Pharmacotherapy

Autism

- Rituals are frequently mistaken for OCD!
 - High-dose SSRI/TCA often contribute to hyperarousal
- Hyperarousal: Short-term Benzodiazepines
 - In Patients prone to sensory overload
 - Low-Dose Neuroleptics
 - Low-Dose-VPA

Psychoeducation

Milieutherapy

- Oxytocin may improve social interaction
- SSRI and CBD may improve anxiety and irritability
- Sle
 - Sleep-disorders: Melantonin





Treatment and Education of Autistic and related Communication handicapped CHildren

Milieutherapy

Psychoeducation

Psychotherapy





Pharmacotherapy

Milieutherapy

Psychoeducation

Psychotherapy



TEACCH

- Visualising of daily routine
- Initializing using pictograms
- Positive reinforcement





Milieutherapy

Psychoeducation

Psychotherapy

TEACCH

- Visualising of daily routine
- Initializing using pictograms
- Positive reinforcement
- Take off pictogram ("finished")
- Work through and end the day





Pharmacotherapy

SEO

- Realizing emotional needs
- **Milieutherapy**
- Concrete recommendations for milieutherapy

Conceptualized approach to use teamwide

Psychoeducation

Helps to adapt care structures


- Improves quality of life
- Helps to lower the drug load





SEO helps to lower the drug load

Total number of different psychotropic medication



p: Mann-Whitney-U/Wilcoxon






Pharmacotherapy

SEO helps to lower the drug load

Total number of different neuroleptic medication




p: Mann-Whitney-U/Wilcoxon





SEO helps to lower the drug load

Neuroleptic Load in mg of Haloperidol-Equivalents



p: Mann-Whitney-U/Wilcoxon





Pharmacotherapy

SEO Diagnostics

SEO-LUKAS

SEO-GB words have been and a second and a se

Milieutherapy

NEED

NEED NETWORK OF EUROPEANS ON EMOTIONAL DEVELOPMENT

Research in Developmental Disabilities

Tanja Sappok "., Brian Fergus Barrett", Stijn Vandevelde", Manuel Hein Leen Poppe ", Paula Sterkenburg ", Jolanda Vonk", Juergen Kolb", Claudia Claes ", Thomas Bergmann", Anton Došen ", Filip Morissed

Psychoeducation

SED-S

- JLD-







Client and social surroundings

Cognitive *and* emotional development

Milieutherapy

Dissociated development

Psychoeducation Phenotype

Multifactorial etiology and therapy

Psychotherapy Diathesis–Stress Model

Functionality





Pharmacotherapy

Psychoanalytic Therapy

Intrapsychic conflicts

Familially conflicts

Psychodynamic processes

Behavioral Therapy (BT)

Closer to the client

Easier to adapt to IDD

More promising results

Milieutherapy

Psychoeducation





Necessary adaptations to BT for IDD

Milieutherapy

Visualizations

Shorter but more frequent sessions

Psychoeducation More structure

Simple language

Behavioral Therapy

Playful elements

As concrete as possible without abstractions





Pharmacotherapy

Available adaptations of BT for IDD

Milieutherapy

Interpersonal Psychotherapy (IPT)

Psycho-

Motivational Interviewing

education

Emotion- and Impulseregulation (DBT-ID)

Behavioral Therapy

Social Skill Training

Operant conditioning (Token Economies)








DBT-ID ISBN: 978-3-921900-36-9


brian.barrett@stiftung-liebenau.de www.stiftung-liebenau.de www.eamhid.eu www.seo-gb.net



DM-ID-2 ISBN: 978-1572561342



Došen et al. ISBN: 978-0880488501



Bertelli et al. ISBN: 978-3-319-95719-7





Download the Handouts of this Masterclass here!



www.eamhid.eu/masterclasses